
Is There a Tirzepatide Pill? Oral Options in 2026
Is there a tirzepatide pill? No: tirzepatide is injection-only. The approved GLP-1 pills (Foundayo, Wegovy pill), results, prices, and oral tirzepatide risks.
Written by Nataliia Bondarchuk. Updated October 22, 2026.
No. As of October 2026 there is no FDA-approved tirzepatide pill. Tirzepatide, sold as Mounjaro and Zepbound, is only approved as a once-weekly injection. If you want a GLP-1 medicine you can swallow, the approved options are different drugs: Lilly's Foundayo (orforglipron), the Wegovy pill (oral semaglutide) for weight loss, and Ozempic tablets for type 2 diabetes. "Oral tirzepatide" drops, tablets or sublingual products sold online are not approved and have not been shown to work.
Why Tirzepatide Is an Injection
Tirzepatide is a peptide, a chain of 39 amino acids. Stomach acid and digestive enzymes break peptides down, and very little gets through the gut wall into the blood. That is why tirzepatide is injected under the skin once a week. Semaglutide pills only work because they use a special absorption enhancer and strict fasting rules, and even then only a small fraction of the dose is absorbed.
Approved GLP-1 Pills in 2026
GLP-1 pills you can get in the US (October 2026)
Drug
Orforglipron (Lilly)
Semaglutide (Novo Nordisk)
Semaglutide (Novo Nordisk)
Approved for
Weight management
Weight management
Type 2 diabetes
Type of molecule
Small molecule, not a peptide
Peptide with absorption enhancer
Peptide with absorption enhancer
Food rules
No fasting needed
Empty stomach, up to 4 oz water, wait 30 min
Empty stomach, up to 4 oz water, wait 30 min
Average weight loss, main trial
About 12% at the highest dose (ATTAIN-1)
About 13.6% at 25 mg (OASIS 4)
Smaller; studied for blood sugar
Self-pay price
From $149 a month
From $149 a month
From $149 a month
How Do the Pills Compare With Tirzepatide Injections?
Tirzepatide injections still produce the most weight loss of any approved drug: about 20.9% on average at 15 mg in SURMOUNT-1. The pills land lower, around 12% to 14%. For many people the convenience of a daily pill, or avoiding needles, is worth that trade-off; for others the larger effect of the weekly shot matters more. See tirzepatide weight loss by week and the tirzepatide dosage guide.
What About Oral Tirzepatide Sold Online?
Some telehealth companies and websites sell "oral tirzepatide" as drops, dissolving tablets or capsules. None are FDA-approved, none have published trials showing they work, and the FDA has warned about unapproved and compounded GLP-1 products, including dosing errors and products of unknown quality. Given how poorly peptides are absorbed by mouth, there is little reason to expect these products to deliver a meaningful dose.
Is Lilly Developing a Tirzepatide Pill?
Lilly's oral strategy is orforglipron, a small molecule that can be absorbed as a pill, rather than a tablet version of tirzepatide. Lilly's next-generation research is focused on combinations such as EloraTZP and on retatrutide; see what comes after tirzepatide.
Bottom Line
There is no tirzepatide pill. Tirzepatide remains a weekly injection with the strongest average weight loss. If you need a pill, Foundayo and the Wegovy pill are the approved choices, with somewhat smaller results. Avoid unapproved "oral tirzepatide" products. To compare the main injectable options, read tirzepatide vs semaglutide.
FAQ
No. Tirzepatide is only approved as a once-weekly injection as of October 2026.
No. Foundayo is orforglipron, a different GLP-1 drug from Lilly that works as a daily pill.
There is no published evidence that they do, and they are not FDA-approved.
In trials, the Wegovy pill (about 13.6%) and Foundayo (about 12% at the top dose) are similar. Both are below tirzepatide injections.
Yes, with your prescriber, who will start the pill at its own starting dose.
Sources
- 1Eli Lilly reports FDA approval of Foundayo (orforglipron), PharmaShots, April 2026
- 2SURMOUNT-1: tirzepatide once weekly for the treatment of obesity, New England Journal of Medicine, 2022
- 3Wegovy prescribing information (pen and pill), Novo Nordisk
- 4FDA's concerns with unapproved GLP-1 drugs, FDA

Nataliia Bondarchuk
Author
Comments (0)
Be the first to comment on this article.




